

Supplementary information

Crossover randomized multicentre clinical trial comparing the efficacy and tolerability of fixed-combinations of 0.1% brimonidine/0.5% timolol versus 1% dorzolamide/0.5% timolol as adjunctive therapies to prostaglandin analogues: Aibeta Crossover Study

Masaru Inatani,^{1,*} Yusuke Orie,¹ Kentaro Iwasaki,¹ Shogo Arimura,¹ Hiromi Sunagawa,² Minako Shiokawa,² Kenji Inoue,² Takuto Sakono,³ Takato Sakono,³ Rika Kuwamura,⁴ Akiko Yoshida,⁴ Junko Oi,⁴ Yasuaki Kuwayama,⁴ Kiyoshi Kano,⁴ Noriaki Kido,⁵ Akiko Matsuyama,⁶ Mineo Ozaki,⁶ Hideki Abe,⁷ Chizuru Inoue,⁷ Satoko Nakagawa,⁷ Kunihiro Musashi,⁷ Akiyasu Kanamori,⁸ Jinhee Lee,⁹ Shinichiro Otani,⁹ Ryota Aoki,¹⁰ Hirotaka Tanabe,¹⁰ Shunsuke Nakakura,¹⁰ Katsuyoshi Suzuki,¹¹ Takeshi Sagara,¹² Yoshiaki Saito,¹³ Motoyasu Sameshima,¹⁴ Mai Urahashi,¹⁵ Fumika Watanabe-Kitamura,¹⁵ Toshihiro Inoue,¹⁵ Fumie Kagaya,¹⁶ Yusuke Murai,¹⁷ Sotaro Mori,¹⁷ Kaori Ueda,¹⁷ Takuji Kurimoto,¹⁷ Yuko Yamada-Nakanishi,¹⁷ Makoto Nakamura,¹⁷ Takehiro Yamashita,¹⁸ Sosuke Ishiyama,¹⁹ Shinichi Manabe,¹⁹ Keiko Takaki,¹⁹ Ken Hayashi,¹⁹ Akiko Ishida,²⁰ Aika Tsutsui,²⁰ Kaoru Manabe,²⁰ Masaki Tanito,²⁰

¹ Department of Ophthalmology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

² Inouye Eye Hospital, Tokyo, Japan.

³ Igo Ophthalmic Clinic, Kagoshima, Japan.

⁴ Fukushima Eye Clinic, Osaka, Japan.

⁵ Midorino Eye Clinic, Hyogo, Japan.

⁶ Ozaki Eye Hospital, Miyazaki, Japan.

⁷ Musashi Dream Clinic, Osaka, Japan.

⁸ Kanamori Eye Clinic, Hyogo, Japan.

⁹ Miyata Eye Hospital, Miyazaki, Japan.

¹⁰ Department of Ophthalmology, Saneikai Tsukazaki Hospital, Hyogo, Japan.

¹¹ Suzuki Eye Clinic, Yamaguchi, Japan.

¹² Sagara Eye Clinic, Yamaguchi, Japan.

¹³ Saito Eye Clinic, Ishikawa, Japan.

¹⁴ Sameshima Eye Clinic, Kagoshima, Japan.

¹⁵ Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

¹⁶ Kagoshima Miyata Eye Clinic, Kagoshima, Japan.

¹⁷ Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Hyogo, Japan.


¹⁸ Yamashita Eye Clinic, Kagoshima, Japan.

¹⁹ Hayashi Eye Hospital, Fukuoka, Japan.

²⁰ Department of Ophthalmology, Shimane University Faculty of Medicine, Shimane, Japan.

Table of contents		Page
Supplementary Figure 1	Changes in intraocular pressures (IOPs) (mean of 0- and 2-hour) before and after the administration of 0.1% brimonidine/0.5% timolol fixed-combination (BTFC) and 1% dorzolamide/0.5% timolol fixed-combination (DTFC).	2
Supplementary Table 1	Score-worsening of ocular surface condition by two or more.	3

Supplementary Figure 1. Changes in intraocular pressures (IOPs) (mean of 0- and 2-hour) before and after the administration of 0.1% brimonidine/0.5% timolol fixed-combination (BTFC) and 1% dorzolamide/0.5% timolol fixed-combination (DTFC).



The IOPs at all measurement time points after the administration were significantly lower than the IOPs during Visit 1 ($P < 0.0001$, paired t-test).

The error bar indicates the standard deviation.

Supplementary Table 1. Score-worsening of ocular surface condition by two or more.

			4-week		8-week	
			0-hour	2-hour	0-hour	2-hour
BTFC		n	124	124	174	174
	Conjunctiva	Hyperaemia	0	0	0	0
		Oedema	0	0	0	0
		Follicle	0	0	0	0
	Eyelid	Erythema	0	0	0	0
		Oedema	0	0	0	0
	Cornea (AD classification)	Area	1 (0.8%)	1 (0.8%)	3 (1.7%)	4 (2.3%)
		Density	0	0	1 (0.6%)	1 (0.6%)
DTFC		n	122	122	178	172
	Conjunctiva	Hyperaemia	0	0	0	0
		Oedema	0	0	0	0
		Follicle	0	1 (0.8%)	0	0
	Eyelid	Erythema	0	0	0	0
		Oedema	0	0	0	0
	Cornea (AD classification)	Area	0	0	3 (1.7%)	6 (3.5%)
		Density	2 (1.6%)	1 (0.8%)	2 (1.1%)	4 (2.3%)

Number of eyes